Patent · US Active

Compositions and methods for inhibiting expression of Eg5 gene

US7718629B2 · kind B2 · utility

211Cited by

29References

33Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

David Bumcrot · Belmont, US
Pamela Tan · Kulmbach, DE
Hans-Peter Vornlocher · Bayreuth, DE
Anke Geick · Bayreuth, DE

Key dates

Filing date	Mar 30, 2007
Grant date	May 18, 2010
Priority date	—
Expiry date	Apr 7, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2330/30
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.